Caroline Seymour

Concurrent frontline therapy with cladribine and rituximab led to a significant improvement in minimal residual disease–free complete responses versus cladribine followed by delayed rituximab in patients with hairy cell leukemia.

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

Preetesh Jain, MD, PhD, evaluates mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Preetesh Jain, MD, PhD, evaluated mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

David D. Thiel, MD, discussed the results of a CCGA study and the next steps with this research.

Michael Wang, MD, discusses paradigm shifts in lymphomas and the research efforts driving precision medicine in mantle cell lymphoma.

Michael Wang, MD, discusses paradigm shifts in lymphomas and the research efforts driving precision medicine in mantle cell lymphoma.

The combination of gemcitabine and ribociclib led to a radiographic and histologic response in a woman with chemotherapy-resistant metastatic CDK6-amplified osteosarcoma

Joyce A. O'Shaughnessy, MD, sheds light on the current paradigm of HER2-positive breast cancer and the optimal role of neratinib in the early-stage and advanced settings.

Joyce A. O'Shaughnessy, MD, sheds light on the current paradigm of HER2-positive breast cancer and the optimal role of neratinib in the early-stage and advanced settings.

Prithviraj Bose, MD, discusses the role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and other novel agents under exploration.

Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib. 

Allyson Ocean, MD, discusses some of the key initiatives that she has helped spearhead to raise awareness on COVID-19 and provide PPE to those who need it.

David S. Hong, MD, discusses the results of these analyses with larotrectinib in patients with NTRK alterations.

Shai Friedland, MD, discusses the importance of screening for colorectal cancer, the advantages of the noninvasive FirstSightCRC blood test, and the results from the ZENITH trial.

Paul M. Barr, MD, discusses the findings from a phase 1/2 trial and the evolution toward triplet therapies in chronic lymphocytic leukemia.

R. Wendel Naumann, MD, discusses the FDA approval of niraparib in ovarian cancer and the impact on the current treatment paradigm.

Edward B. Garon, MD, MS, discusses the importance of the GEOMETRY mono-1 study in patients with advanced NSCLC who harbor MET exon 14 skipping mutations.

Allyson Ocean, MD, discusses the emotional toll COVID-19 has had on patients and practitioners and the importance of self-care and social distancing.

Nizar M. Tannir, MD, FACP, discusses the 42-month follow-up results from the CheckMate-214 trial in advanced renal cell carcinoma and provides perspective on other approved combinations in the frontline setting.

Quantitative microelastography demonstrated increased sensitivity, specificity, and accuracy in detecting positive surgical margins in combination with optimal coherence tomography versus optimal coherence tomography alone in women who received breast-conserving surgery.

Gina Z. D'Amato, MD, discusses the evolution of treatment in sarcoma, the use of next-generation sequencing, and predictive and prognostic biomarkers under investigation in the space.

R. Lor Randall, MD, FACS, discusses current approaches in the surgical management of patients with osteosarcoma that has metastasized to the lungs.

John N. Allan, MD, discusses the study results of a phase 1b/2 dose-escalation trial with vecabrutinib in patients with B-cell malignancies.

Christopher E. Dandoy, MD, MSc, discusses the clinical features of TA-TMA and the importance of close monitoring and intervention for patients at risk of developing the disorder.

Rana R. McKay, MD, discusses the results of the real-world analysis with radium-223 and other exciting research in the mCRPC field.

Allyson Ocean, MD, explains how the outbreak has impacted treatment plans for patients, and sheds light on the work being done to develop a treatment and/or vaccine for the virus.

Rajat Bannerji, MD, PhD, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma.

Robert J. Kreitman, MD, discusses the long-term findings from the pivotal phase III trial with moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.